Nash Pharmaceuticals Inc is a privately held
drug development company focusing on developing
repurposed therapeutic drugs. The company has
developed data that supports the advancement of
up to 7 drug candidates into phase II trials in
the areas of non–alcoholic steatohepatitis
(NASH), chronic kidney disease (CKD) and
inflammatory bowel disease (IBD).